CCKAR and obesity disorder: For the present study, EP/T inhibition with camostat metabolite FOY-251 was used as a tool molecule to understand the mechanistic role of CCK1R activation in the metabolic effects of EP/T inhibitor approach, however, differentiated development strategies for either EP/T or CCK1R targets may ultimately lead to the chemical matter with drug-like properties for human obesity.